ArticleFrontiers in cardiovascular medicine2025
Serum JKAP as a potential prognostic biomarker in acute coronary syndrome patients undergoing percutaneous coronary intervention.
Article in Frontiers in cardiovascular medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: Our previous studies revealed that knockdown of JNK pathway-associated phosphatase (JKAP) facilitates atherosclerotic progression by regulating CD4 Methods: This study included 173 ACS patients, for whom serum JKAP levels were detected before PCI and 1 month (M1) after PCI via an enzyme-linked immunosorbent assay. Short physical performance battery (SPPB) scores at M1 and major adverse cardiac event (MACE) data were collected. Moreover, serum JKAP levels were detected in 32 healthy control subjects. Results: JKAP levels were significantly lower in ACS patients vs. healthy control subjects ( Conclusion: JKAP may serve as a prognostic biomarker in ACS patients who have undergone PCI.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.